AD/PD 2022 | Potential targets for Parkinson’s disease treatment

Fabrizio Stocchi, MD, PhD, IRCCS San Raffaele Rome, Sapienza University of Rome, Rome, Italy, outlines potential targets for Parkinson’s disease treatment. α-synuclein is a promising target, as an increase of α-synuclein is observed across different types of parkinsonian syndromes. Gene mutations, particularly GBA and LRRK2, could also be a focus for drugs. Inflammation, a putative risk factor and cause of Parkinson’s disease, is another promising target. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.